Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 20/12/2021, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Kigabeq, vigabatrin, Date of authorisation: 20/09/2018, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Adzynma, rADAMTS13, Date of authorisation: 01/08/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group

Pharmacovigilance-related regulatory recommendations for centrally authorised veterinary medicinal products during 2026

Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 13, Status: Authorised